FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA

Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.